Abstract
Purpose:
To investigate the safety and efficacy of intravitreal bevacizumab or ranibizumab therapy for treatment of choroidal neovascularization (CNV) associated with choroidal osteoma.
Methods:
Retrospective, observational, consecutive case series of patients diagnosed with choroidal osteoma and CNV who were treated with intravitreal bevacizumab and/or ranibizumab, on the Retina or Oncology Services of the Wills Eye Hospital, Philadelphia, PA.
Results:
Six tumors in six eyes were treated with intravitreal anti-VEGF therapy. Mean tumor basal diameter was 8.9 mm (range 4.5 - 14 mm), with mean tumor thickness 1.2 mm (range 1.0 - 1.6 mm). A mean of 10 intravitreal injections were completed (median 9, range 3 - 19 injections), with regression of CNV and resolution of fluid on optical coherence tomography achieved in 5 of 6 (83%) cases. Two tumors required 1 session of photodynamic therapy (PDT) for control in addition to anti-VEGF therapy. Improvement or stability of visual acuity was observed in 5 of 6 eyes (83%, range 0 to 6 Snellen line improvement). Patients were followed over a mean period of 21 months (median 18, range 5 to 56 months), with one complication (traumatic cataract) observed.
Conclusions:
Therapy with intravitreal bevacizumab and/or ranibizumab can be effective for CNV secondary to choroidal osteoma, with resolution of CNV and preservation of visual acuity.
Keywords: 744 tumors •
453 choroid: neovascularization